Hypophosphatasia (HPP) Medication

Updated: Jun 05, 2023
  • Author: Ricardo R Correa Marquez, MD, EsD, FACP, FACE, FAPCR, CMQ, ABDA, FACHT; Chief Editor: Luis O Rohena, MD, PhD, FAAP, FACMG  more...
  • Print

Medication Summary

Until 2015, no effective drug therapy had been approved for hypophosphatasia. The FDA approved asfotase alfa as the first-ever therapy for hypophosphatasia caused by a rare hereditary mutation in alkaline phosphatase gene. [15, 16]


Enzymes, Metabolic

Class Summary

Enzyme replacement therapy helps to prevent bone demineralization.

Asfotase alfa (Strensiq)

Enzyme replacement that is a soluble glycoprotein composed of 2 identical polypeptide chains; each chain consists of the catalytic domain of human tissue–nonspecific alkaline phosphatase (TNSALP), the human immunoglobulin G1 Fc domain and a deca-aspartate peptide used as a bone-targeting domain. It is indicated for perinatal/infantile- and juvenile-onset hypophosphatasia.